Skip to content
Prader-Willi Syndrome News logo Newsletter
Newsletter
  • Prader-Willi Syndrome News on Facebook
  • About Prader-Willi
    What is Prader-Willi?
    Causes
    Symptoms
    Diagnosis
    Treatments
    • Vykat XR
    • Somatropin
  • News
  • Columns
    Choosing Happiness — Janet Favorite
    Finding Joy in the Journey — Paige Rivard
  • Quizzes
    PWS basics
    Lifestyle and diet
  • What can we help you find today?

    • Prader-Willi Syndrome News on Facebook

Prader-Willi syndrome treatment

Last updated Sept. 25, 2025, by Lindsey Shapiro, PhD
✅ Fact-checked by Marta Figueiredo, PhD

Treatment options
Lifestyle changes
Emerging treatments

 

Prader-Willi syndrome (PWS) treatment involves interventions to control disease symptoms, as there are currently no therapies that directly address the underlying PWS causes.

The genetic disorder is caused by the loss or inactivation of specific genes on the paternally inherited chromosome 15. This leads to a wide range of PWS symptoms, including stunted growth, developmental delays, insatiable hunger, obesity, and behavioral challenges.

While there is no cure for PWS, early intervention after a PWS diagnosis is key for managing symptoms and preventing the long-term health problems that can occur secondarily to uncontrolled eating and obesity.

Prader-Willi syndrome treatment options

PWS treatment involves a multidisciplinary approach that varies based on a person’s age and symptoms.

Growth hormone therapy, in the form of the lab-made human growth hormone somatropin, is a standard PWS treatment because nearly all children and many adults with the disease are deficient in naturally produced growth hormone.

Recommended to be started in early childhood, PWS growth hormone therapy has several benefits, such as increased height, lower body fat, greater muscle mass, better bone health, and improved physical and cognitive performance.

Somatropin, given via under-the-skin injections, is approved in the U.S. to treat growth failure in children with PWS under the brand names Genotropin and Norditropin, with a biosimilar available. These and other brand names can also be used in pediatric and adult PWS patients upon verification of growth hormone deficiency.

Also key to PWS management is controlling insatiable hunger, or hyperphagia, that starts in childhood and results in extreme food-seeking behaviors, obesity, and related health complications. Treatment for hyperphagia may involve:

  • Vykat XR (diazoxide choline), a daily oral therapy designed to reduce appetite that’s approved in the U.S. for PWS patients ages 4 years and older
  • strict food control and constant supervision when food is accessible
  • a well-balanced, low-calorie PWS diet and frequent exercise to aid in weight management

Supportive care for PWS may also involve, but is not limited to:

  • tube feeding, to provide adequate nutrition to infants
  • sex hormone replacement therapy in PWS, to address low levels of sex hormones (testosterone in boys and estrogen and progesterone in girls)
  • sleep management, including medications to reduce excessive daytime sleepiness
  • therapeutic strategies, including surgery, to correct orthopedic issues like scoliosis
  • physical and occupational therapy to combat low muscle tone and motor delays
  • speech therapy to improve verbal skills
  • medications or behavioral therapy for PWS to manage mood and behavior problems

Lifestyle changes

PWS management may also involve a range of lifestyle changes, typically implemented or promoted by parents, to minimize how intrusive PWS symptoms become in daily life. They include:

  • sticking to a strict daily routine and setting clear expectations, particularly in terms of meal times
  • engaging in regular physical activity
  • dealing with emotional distress through emotional regulation activities, like quiet spaces and calming strategies
  • having a personalized educational plan, designed together with the schools
  • receiving mental health support through counseling, therapy, or support groups

Various specialists — including dietitians, physical, occupational, and speech therapists — may be brought on board to help families make the appropriate adjustments that work best for their child.

Emerging Prader-Willi syndrome treatments

While there are few available treatments specifically approved for PWS, a number of investigational PWS medications are currently being tested in clinical trials. Examples of therapies in Phase 3 clinical trials for PWS include:

  • ARD-101, an oral therapy designed to lessen hyperphagia
  • pitolisant, an oral medication intended to ease excessive daytime sleepiness

Gene therapies to correct the underlying cause of PWS are of interest to researchers, but no such medications have yet entered clinical trials.


Prader-Willi Syndrome News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Recent Posts

  • Clinical trial being planned to test nasal spray using oxytocin for PWS
  • PWS-related hyperphagia drug ACP-101 fails to meet trial goals
  • How hyperphagia affects patients and their families
  • Potential PWS therapeutic target discovered, study suggests
  • Genetic deletion may drive obesity in PWS adults: Study
  • A group home has benefited my son with Prader-Willi syndrome
  • Riding the emotional roller coaster of caring for my son with PWS
  • Hormone therapy side effects challenge girls with PWS
  • Imbalance of fat molecules predicts risk in children with PWS: Study
  • Helping children with PWS navigate their school systems


Related articles

  1. October 2, 2025 News by Michela Luciano, PhD

    Clinical trial being planned to test nasal spray using oxytocin for PWS

  2. The words
    September 25, 2025 News by Lila Levinson, PhD

    PWS-related hyperphagia drug ACP-101 fails to meet trial goals

  3. banner image for Janet Favorite's column
    September 22, 2025 by Janet Favorite

    How hyperphagia affects patients and their families

  4. A strand of DNA is shown in this illustration.
    September 18, 2025 News by Steve Bryson, PhD

    Potential PWS therapeutic target discovered, study suggests

  5. A close-up illustration of a DNA strand highlights its ribbon-like structure.
    September 11, 2025 News by Lila Levinson, PhD

    Genetic deletion may drive obesity in PWS adults: Study

  6. banner image for Janet Favorite's column
    September 8, 2025 by Janet Favorite

    A group home has benefited my son with Prader-Willi syndrome

Swipe left to view more
Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

This field is for validation purposes and should be left unchanged.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  • Prader-Willi Syndrome News on Facebook
Copyright © 2013-2025 All rights reserved.